SPY442.84-1.07 -0.24%
DIA350.16+2.29 0.66%
IXIC14,898.05-149.65 -0.99%

Merck, Ridgeback Biotherapeutics Launch Phase 3 Trial of Potential COVID-19 Antiviral Molnupiravir

MT Newswires · 09/01/2021 03:34

Please log in to view news